



70% will fail in the first 20 months.

97% of startups will fail.





One door for foreign direct investment and open innovation



One door for rapid commercialization and scale





COMMERCIALIZE. CAPITALIZE. ACCELERATE R&D & CLINICAL PATHWAYS

Accelerated
Regulatory
Pathway into EU

Strategic partnerships

Investment opportunities from our investor network

Networking opportunities


Mentorship

Office space and other accommodations

Regional Scale

Tech Perks

FOUNDERS WHO EXIT \$6M - \$1.2B 10 COMMON TRAITS Money | Initiation | Automatic | Power | Breadth



Assertiveness | Depth | Procedures | External | Structure



100% FOUNDERS FIRST

WORLD FIRST AI STARTUP COACH

1:1 MENTORING AND COACHING



WE SUPPORT HEALTHCARE SYSTEM BY REMOVING UNNECESSARY TIME DELAYS IN EMERGENCIES

Andrej Studencan, CEO



ViewMind's digital
biomarkers for detecting
neurocognitive diseases

VR & Eye-tracking test

Non-invasive & Standardized

Medical Software & A.I. Algorithms

Detection in early stages







ACCELERATE YOUR R&D AND CLINICAL PATHWAYS



Collaborates with more than 40 partners in cybersecurity, fintech, space systems, IOT, Autonomous Vehicles...



Focus on neurodegenerative diseases with a strong bioinformatics, computational and systems biology approach.

Over 6.000 students

from more than 100 different countries



12th worldwide in Young University ranking

(Times Higher Education 2020)



Biomedical sciences research with strong expertise in oncology, infection and immunity.



Research and Technology Organisation active in the fields of materials, environment and IT.



"Through the House of MedTech incubation program, we have been privileged and grateful to have forged a working relationship with an esteemed PI at the Luxembourg Institute of Health, to validate our digital solution in the context of diabetes prevention.

This now puts us on a path to secure CE Mark regulatory approval, accelerate our access to non-dilutive and smart capital, and firmly positions our European HQ for international scale."



WHAT KIND OF COMPANIES SHOULD APPLY?

01

SCALEUP
DEEPTECH OR
MEDTECH
PATENT PORTFOLIO

02

COMMERCIALIZATION
CAPITALIZATION
ACCELERATED R&D

03

STRONG PRODUCT MARKET FIT EXISTING REVENUES IN AT LEAST 1 MARKET READY FOR CROSS BORDER SCALEUP



JOIN THE WORLD'S **LARGEST** WOMEN'S **STARTUP** COMPETITION IS NOW IN JAPAN & LUXEMBOURG



HOUSEOFDEEPTECH

ACCELERATE IMPACT

Leesa Soulodre, General Partner R3i Ventures

<u>Leesa@r3iventures.com</u>

Whatsapp: +65 81862155